DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
77
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Avid Technology, Inc. (AVID) and Lead Plaintiff Deadline: January 20, 2017

NEW YORK, Jan. 11, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Avid Technology, Inc. (“Avid” or the “Company”) (NASDAQ: AVID ) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Avid securities between August 4, 2016 and November 9, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/avid .

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that because it did not launch all the enterprise level features for its new NEXIS solution product offerings, its enterprise clients were suspending renewals and purchases. 

On November 9, 2016 Avid revealed that its third quarter 2016 bookings and revenues were much lower than how it was forecasted and told to investors. Avid said, “the transition of the storage product line” and divulging that “some existing enterprise clients deferred normal upgrade and renewal decisions and new customers postponed investments until the release of functionality targeted to the enterprise market.”

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: www.bgandg.com/avid or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Avid you have until January 20, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.  Attorney advertising. Prior results do not guarantee similar outcomes.

Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | info@bgandg.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 12

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 5

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 7

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Taseko Mines Earnings: Missed Estimates or Surprising Upside?

Updated Category News Views 144

Taseko Mines (AMEX:TGB) is set to drop its quarterly earnings report on February 18, 2026, and traders are already buzzing about it. The whispers in the hallways suggest a glimmer of hope, with analysts eyeing an earnings per share (EPS) of $0.08—a target that could shift market sentiments depending on how it lands. The last quarter's performance still stings; Taseko...

Continue Reading
Magnet Biomedicine Enhances Research with Simplicis's Ledger™

Updated Category News Views 173

Magnet Biomedicine Partners with Simplicis's Ledger™ Platform Magnet Biomedicine, a pioneering biotechnology firm focused on advancing molecular glue discovery, has recently chosen Simplicis's Ledger™ platform following a thorough assessment of leading alternatives. This decision reflects a commitment to enhancing research operations and optimizing compound management...

Continue Reading
Forecasting Asset Appreciation: Bitcoin and Gold's Potential Rise

Updated Category News Views 114

Understanding Market Dynamics Under Uncertain Political Landscapes In the world of finance, significant political changes can lead to substantial shifts in market dynamics. Recent insights from JPMorgan analysts suggest that a victory for Donald Trump could lead to a spike in both Bitcoin and gold prices. This projection is rooted in growing interest from retail investors...

Continue Reading
Apple and Google Forge a Powerful AI Partnership for Future

Updated Category News Views 73

Apple and Google's Exciting AI Collaboration With the excitement surrounding artificial intelligence expected to surge into 2026, tech enthusiasts and market analysts alike are keenly observing the landscape. The anticipation is mounting as companies evaluate their AI capabilities, looking to distinguish true leaders from those merely riding the wave of hype. In a...

Continue Reading
Podcasting Industry Set to Hit $114 Billion With New Trends

Updated Category News Views 241

Explosive Growth in the Podcasting Market Podcasting continues to gain massive traction, with predictions estimating the market will skyrocket from USD 31.49 billion now to an impressive USD 114.48 billion by 2030. This remarkable growth, with a compound annual growth rate (CAGR) of 29.45%, is driven by several innovative trends reshaping the media landscape....

Continue Reading